News | July 05, 2023
Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
elanese now offers Zytel Resin, Hytrel TPC, Crastin PBT and Micromax Electronic Inks and Paste following its 2022 acquisition of the majority of the Mobility & Materials (M&M) business from DuPont
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Subscribe To Our Newsletter & Stay Updated
